Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

CNS drug development

Neuroscience

Neuroscience Today—February 18, 2026

This weekly update in neuroscience highlights key regulatory actions, clinical…

Neuroscience

Neuroscience 2025 Review: Disease Modification Meets Deliverability

The defining idea of 2025 was that CNS innovation became an execution…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Oncology Today—March 23, 2026

Tags

AAV exit ANGPTL3 apixaban Arrowhead chronic disease chronic rhinosinusitis CNS metastases Datopotamab Deruxtecan discovery platforms Eisai F2–F3 Factor Bioscience FOR46 genome editing George Institute for Global Health hypogonadism imlunestrant Infinity InnoCare Pharma innovative designs KMT2A lenacapavir Liver disease lyr-100 MFDS Korea modifiable risk factors Neurofibromatosis Type 1 neuropeptide Y NORD Oncology Innovation Oncology investments Paltusotine Primary hyperparathyroidism PRISM AI radiology Remsima IV liquid RPDD sBLA Sirius Therapeutics Sonrotoclax Staphylococcus aureus vaccine STELARA Tavapadon Tetralogy of Fallot venture funding vorasidenib

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Oncology Today—March 23, 2026

TAGS

AAV exit ANGPTL3 apixaban Arrowhead chronic disease chronic rhinosinusitis CNS metastases Datopotamab Deruxtecan discovery platforms Eisai F2–F3 Factor Bioscience FOR46 genome editing George Institute for Global Health hypogonadism imlunestrant Infinity InnoCare Pharma innovative designs KMT2A lenacapavir Liver disease lyr-100 MFDS Korea modifiable risk factors Neurofibromatosis Type 1 neuropeptide Y NORD Oncology Innovation Oncology investments Paltusotine Primary hyperparathyroidism PRISM AI radiology Remsima IV liquid RPDD sBLA Sirius Therapeutics Sonrotoclax Staphylococcus aureus vaccine STELARA Tavapadon Tetralogy of Fallot venture funding vorasidenib

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy